Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas

Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials

Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works

Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma

Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V. L., Ferraro, R., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W. M., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30496-0 · Cited by 214 · see citing works

Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study

Takahashi, S., Fujiwara, Y., Nakano, K., Shimizu, T., Tomomatsu, J., Koyama, T., Ogura, M., Tachibana, M., Kakurai, Y., Yamashita, T., et al. (2021) · Cancer Science · doi:10.1111/cas.14875 · Cited by 60 · see citing works

Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial

Gounder, M. M., Razak, A. A., Somaiah, N., Chawla, S. P., Martín‐Broto, J., Grignani, G., Schuetze, S. M., Vincenzi, B., Wagner, A. J., Chmielowski, B., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.01829 · Cited by 45 · see citing works

NCT/DKFZ MASTER handbook of interpreting whole-genome, transcriptome, and methylome data for precision oncology

Möck, A., Teleanu, M., Kreutzfeldt, S., Heilig, C. E., Hüllein, J., Möhrmann, L., Jahn, A., Hanf, D., Kerle, I. A., Singh, H. M., et al. (2023) · npj Precision Oncology · doi:10.1038/s41698-023-00458-w · Cited by 36 · see citing works

BI-907828, a novel potent MDM2 inhibitor, inhibits glioblastoma brain tumor stem cells in vitro and prolongs survival in orthotopic xenograft mouse models

Hao, X., Bahia, R. K., Cseh, O., Bozek, D. A., Blake, S., Rinnenthal, J., Weyer-Czernilofsky, U., Rudolph, D., & Artee Luchman, H. (2023) · Neuro-Oncology · doi:10.1093/neuonc/noac271 · Cited by 34 · see citing works

Targeted therapies for the treatment of soft tissue sarcoma

Fuchs, J. W., Schulte, B. C., Fuchs, J. R., & Agulnik, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1122508 · Cited by 31 · see citing works

The Development of p53-Targeted Therapies for Human Cancers

Lu, Y., Wu, M. Y., Xu, Y., & Yu, L. (2023) · Cancers · doi:10.3390/cancers15143560 · Cited by 30 · see citing works

Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification

Elkrief, A., Odintsov, I., Markov, V., Caeser, R., Sobczuk, P., Tischfield, S. E., Bhanot, U. K., Vanderbilt, C., Cheng, E. H., Drilon, A. E. D. C., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.007 · Cited by 21 · see citing works

The ubiquitin-proteasome system in the regulation of tumor dormancy and recurrence

Alhasan, B. A., Morozov, A. V., Guzhova, I. V., & Margulis, B. A. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189119 · Cited by 20 · see citing works

A window-of-opportunity trial reveals mechanisms of response and resistance to navtemadlin in patients with recurrent glioblastoma

Rendo, V., Lee, E. Q., Bossi, C., Khuu, N., Rudek, M. A., Pal, S., Azazmeh, N., Rashid, R., Lin, J.-R., Cusick, M., et al. (2025) · Science Translational Medicine · doi:10.1126/scitranslmed.adn6274 · Cited by 19 · see citing works

Genetic, Epigenetic and Transcriptome Alterations in Liposarcoma for Target Therapy Selection

Lesovaya, E. A., Fetisov, T. I., Bokhyan, B. Y., Павловна, М. В., Kulikov, E. P., Belitsky, G. A., Игоревич, К. К., & Геннадиевна, Я. М. (2024) · Cancers · doi:10.3390/cancers16020271 · Cited by 15 · see citing works

First‐line chemotherapy in advanced intra‐abdominal well‐differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis

Stacchiotti, S., van der Graaf, W. T. A., Sanfilippo, R. G., Marreaud, S. I., van Houdt, W. J., Judson, I. R., Gronchi, A., Gelderblom, H. A. J., Litière, S., & Kasper, B. (2022) · Cancer · doi:10.1002/cncr.34264 · Cited by 10 · see citing works

Population pharmacokinetics

Yin, O. Q. P., & Miller, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819869-8.00032-x · Cited by 4 · see citing works

Emerging predictive biomarkers in the management of bone and soft tissue sarcomas

Haddox, C. L., & Riedel, R. F. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2200169 · Cited by 3 · see citing works

Discovery of N-pyridazin-3-piperidine derivatives acting as p53 activators against breast cancer: In vitro and in silico evaluations

Zhang, A., Tang, B., Zhou, S., Sui, C., He, S., Liu, Y., Li, M., & Qian, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118410 · Cited by 1 · see citing works

Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastomaPreprint

Rendo, V., Lee, E. Q., Bossi, C. C., Khuu, N., Rudek, M. A., Pal, S., Reynolds, A. R. N., Fassinou, A. C. R., Ayoub, G., Lapinskas, E., et al. (2024) · medRxiv · doi:10.1101/2024.08.12.24311893

Protein-protein interaction inhibitors in cancer

Hardcastle, I. R., Goujon-Ricci, J., & Thompson, W. I. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00067-4

Disrupting E3 ubiquitin ligase protein–protein interactions in cancer: chemical modalities, mechanisms, and therapeutic opportunities

Kamel, E. M., Khadrawy, S. M., Ali, M. A. M., Ahmed, N. A., Yassin, N. Y. S., Alkhedhairi, S., Alkhayl, F. F. A., & Lamsabhi, A. M. (2026) · Biochemical Pharmacology · doi:10.1016/j.bcp.2026.117951

76MO Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas

Chen, T. W.-W., Sanfilippo, R. G., Jones, R. L., Schuetze, S. M., Sebio, A., Alvarez, R. M., Bui, N. Q., Ahn, J.-H., Loong, H. H.-F., Cc, Y., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.211 · Cited by 6 · see citing works

LBA89 Efficacy and safety findings from MANTRA: A global, randomized, multicenter, phase III study of the MDM2 inhibitor milademetan vs trabectedin in patients with dedifferentiated liposarcomas

Jones, R. L., Sanfilippo, R. G., Schuetze, S. M., Sebio, A., Álvarez, R. M., Bui, N. Q., Wagner, A. J., Chawla, S. P., Chen, T. W.-W., Pink, D., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.10.091 · Cited by 9 · see citing works

MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas.

Gounder, M. M., Schwartz, G. K., Jones, R. L., Chawla, S. P., Chua-Alcala, V. S., Stacchiotti, S., Wagner, A. J., Cote, G. M., Maki, R. G., Kosela-Paterczyk, H., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.16_suppl.tps11589 · Cited by 9 · see citing works

Abstract CT235: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan versus trabectedin in patients with de-differentiated liposarcomas

Gounder, M. M., Schwartz, G. K., Jones, R. L., Chawla, S. P., Chua-Alcala, V. S., Stacchiotti, S., Wagner, A. J., Cote, G. M., Maki, R. G., Kosela-Paterczyk, H., et al. (2022) · Cancer Research · doi:10.1158/1538-7445.am2022-ct235

Abstract P031: MANTRA: A randomized, multicenter, phase 3 study of the MDM2 inhibitor milademetan (RAIN-32) versus trabectedin in patients with de-differentiated liposarcoma

Gounder, M. M., Schwartz, G., Jones, R. L., Patel, S., Stacchiotti, S., Wagner, A. J., Tirunagaru, V. G., Shah, N., Bryce, R. P., & Doebele, R. C. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-21-p031